Evaluation of the efficacy of buprenorphine injection around the stellate ganglion in pain syndromes of the upper body-half
Completed
- Conditions
- PainSigns and Symptoms
- Registration Number
- ISRCTN59287260
- Lead Sponsor
- Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
Not provided at time of registration
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Pain reduction over the first 8 hours following stellate injection, as calculated from the median of four, two-hourly measurements of present pain reduction using a visual analogue scale (VAS) and compared between buprenorphine and placebo stellate injections<br>2. Absolute pain levels as expressed using a VAS scale and calculated from the median of four, two-hourly measurements of present pain intensity (PPI), each divided by the pre-injection PPI and compared between buprenorphine and placebo stellate injections
- Secondary Outcome Measures
Name Time Method ot provided at time of registration